Linda Pot

⁸⁹Zr-Bevacizumab PET Imaging in Primary Breast Cancer

Sietske B.M. Gaykema, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge et al. · Journal of Nuclear Medicine · 2013 · 166 citations · Full text

Medicine, Nuclear Medicine, Oncology +14

Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model

Arne R.M. van der Bilt, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer‐Bosscha et al. · Clinical Cancer Research · 2012 · 56 citations

Medicine, Oncology, Pharmacology +17

ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody⁸⁹Zr-RG7116

Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub–de Hooge, K. Abiraj et al. · mAbs · 2014 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts

Eva J. ter Weele, Anton G.T. Terwisscha van Scheltinga, Jos G. W. Kosterink et al. · Oncotarget · 2015 · 37 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer

Anton G.T. Terwisscha van Scheltinga, Paul Berghuis, Hilde H. Nienhuis et al. · European Journal of Cancer · 2014 · 19 citations

Medicine, Cancer Biology, Oncology +17